Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 15/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23744736 | 0.92 | PRKAA2 (0.41) | PRKAA2 | |
| SCHEMBL23744584 | 0.91 | HCAR2 (0.42) | CHRM4 | |
| SCHEMBL23744486 | 0.91 | HCAR2 (0.42) | CHRM4 | |
| SCHEMBL23744472 | 0.90 | HRH3 (0.38) | CHEK2CHRM4 | |
| SCHEMBL23744742 | 0.89 | HCAR2 (0.46) | CHEK2CXCR3CHRM4 | |
| SCHEMBL26429683 | 0.89 | CHEK2 (0.39) | CHEK2 | |
| SCHEMBL26434902 | 0.87 | CHEK2 (0.46) | CHEK2CXCR3CHRM4 | |
| SCHEMBL23744724 | 0.84 | CHRM2 (0.39) | CHRM4PRKAA2 | |
| SCHEMBL26429665 | 0.82 | CCR1 (0.36) | PRKAA2 | |
| SCHEMBL23744451 | 0.82 | HCAR2 (0.44) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2021158698-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | NEUROCRINE BIOSCIENCES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129359-A1 | MUSCARINIC RECEPTOR 4 ANTAGONISTS AND METHODS OF USE | CHRM4, CHRM2, CHRM5 | CHEK2 1536/4885CXCR3 281/4885CHRM4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.